阿奇夫生命科学

Achieve Life Sciences Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 1% premium over our quantitative fair value estimate of $7.14 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of -2.0% ranks in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.

The company's lack of growth is an additional cause for concern. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's revenue 5-year growth of 0%, for example, falls in the bottom 20% globally. Weak trailing five-year revenue growth is disappointing and could indicate trouble generating future value for shareholders, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.